Toll Free: 1-888-928-9744

Open-Angle Glaucoma - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 121 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Open-Angle Glaucoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Open-Angle Glaucoma - Pipeline Review, H1 2016', provides an overview of the Open-Angle Glaucoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
- The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Open-Angle Glaucoma Overview 10 Therapeutics Development 11 Pipeline Products for Open-Angle Glaucoma - Overview 11 Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 12 Open-Angle Glaucoma - Therapeutics under Development by Companies 13 Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 16 Open-Angle Glaucoma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Open-Angle Glaucoma - Products under Development by Companies 21 Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 23 Open-Angle Glaucoma - Companies Involved in Therapeutics Development 24 Aerie Pharmaceuticals, Inc. 24 Allergan Plc 25 Amakem NV 26 Asahi Kasei Pharma Corp. 27 Bausch & Lomb Incorporated 28 F. Hoffmann-La Roche Ltd. 29 Inotek Pharmaceuticals Corporation 30 Kowa Company, Ltd. 31 Lee's Pharmaceutical Holdings Limited 32 Ocular Therapeutix, Inc. 33 Ono Pharmaceutical Co., Ltd. 34 Otsuka Holdings Co., Ltd. 35 Oxford BioMedica Plc 36 Sanofi 37 Santen Pharmaceutical Co., Ltd. 38 Senju Pharmaceutical Co., Ltd. 39 Sun Pharma Advanced Research Company Ltd. 40 Sylentis S.A.U. 41 ViSci Ltd. 42 vTv Therapeutics LLC 43 Open-Angle Glaucoma - Therapeutics Assessment 44 Assessment by Monotherapy Products 44 Assessment by Combination Products 45 Assessment by Target 46 Assessment by Mechanism of Action 49 Assessment by Route of Administration 51 Assessment by Molecule Type 53 Drug Profiles 55 (carteolol hydrochloride + latanoprost) - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 (dorzolamide hydrochloride + latanoprost) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 (latanoprost + trabodenoson) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 (tafluprost + timolol maleate) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AMA-0076 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ATS-8535 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 bamosiran - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 bimatoprost - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 bimatoprost SR - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 DE-117 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 decorin - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Glaucoma-GT - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 HPP-851 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 latanoprost - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 latanoprost - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 latanoprost SR - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 latanoprost SR - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 latanoprostene bunod - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 levobetaxolol hydrochloride - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 netarsudil mesylate - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 ONO-9054 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 OPA-6566 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 R-801 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 RG-4929 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 ripasudil - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 RO-5093151 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 SAR-366234 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecules to Antagonize CXCR3 for Glaucoma - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 SNJ-1656 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 trabodenoson - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 travoprost SR - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Open-Angle Glaucoma - Recent Pipeline Updates 97 Open-Angle Glaucoma - Dormant Projects 112 Open-Angle Glaucoma - Discontinued Products 113 Open-Angle Glaucoma - Product Development Milestones 114 Featured News & Press Releases 114 Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 114 Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 114 Sep 22, 2015: Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO (latanoprostene bunod) 115 Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 116 Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 117 Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 117 Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 118 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121
List of Tables
Number of Products under Development for Open-Angle Glaucoma, H1 2016 11 Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Development by Companies, H1 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 24 Open-Angle Glaucoma - Pipeline by Allergan Plc, H1 2016 25 Open-Angle Glaucoma - Pipeline by Amakem NV, H1 2016 26 Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2016 27 Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2016 28 Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29 Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2016 30 Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H1 2016 31 Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 32 Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2016 33 Open-Angle Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 34 Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 35 Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H1 2016 36 Open-Angle Glaucoma - Pipeline by Sanofi, H1 2016 37 Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 38 Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 39 Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 40 Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H1 2016 41 Open-Angle Glaucoma - Pipeline by ViSci Ltd., H1 2016 42 Open-Angle Glaucoma - Pipeline by vTv Therapeutics LLC, H1 2016 43 Assessment by Monotherapy Products, H1 2016 44 Assessment by Combination Products, H1 2016 45 Number of Products by Stage and Target, H1 2016 47 Number of Products by Stage and Mechanism of Action, H1 2016 50 Number of Products by Stage and Route of Administration, H1 2016 52 Number of Products by Stage and Molecule Type, H1 2016 54 Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H1 2016 97 Open-Angle Glaucoma - Dormant Projects, H1 2016 112 Open-Angle Glaucoma - Discontinued Products, H1 2016 113


List of Figures
Number of Products under Development for Open-Angle Glaucoma, H1 2016 11 Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy Products, H1 2016 44 Assessment by Combination Products, H1 2016 45 Number of Products by Top 10 Targets, H1 2016 46 Number of Products by Stage and Top 10 Targets, H1 2016 46 Number of Products by Top 10 Mechanism of Actions, H1 2016 49 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 49 Number of Products by Routes of Administration, H1 2016 51 Number of Products by Stage and Routes of Administration, H1 2016 51 Number of Products by Molecule Types, H1 2016 53 Number of Products by Stage and Molecule Types, H1 2016 53

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demand

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify